Rafarma Pharmaceuticals Inc (PK) (RAFA) Quote

Sounds like they are out of business. No assets outside of Russia. No auditor will touch them.

Haven't been on the RAFA chat in about a year. How's it going? Told you I'd see you at .05. so glad i sold mine at .45. 50% haircut, so not thrilled but at least not a nickle.

yea thats pretty when the stock flies. its right after you sell. happens all the time.

sold all rafa im off this ride lies and more lies i have wait 5 years no more waiting

Interesting that the CEO said that he sees a $2 billion asset structure in 18 months. I like it.

https://finance.yahoo.com/news/rafarma-pharmaceutical-updates-registration-rafarma-133000510.html

Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.

Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.

Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.

Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.

The main idea of ??radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.

The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.

Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.

Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.

No. No assets to audit yet outside of Russia. So it’s a pretty big joke because no auditor will touch it.

is there anything to audit

when was that letter put out? ty

Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea

July 04, 2024 09:30 ET | Source: Rafarma Pharmaceuticals Inc.

Share

Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.

Currently, procedure is underway to register Yttrium 90 microspheres produced by Rafarma in South Korea, with a view to their subsequent pharmaceutical distribution in Korea. South Korea is the only Asian country with health insurance to use yttrium 90 microspheres for liver cancer patients.

Nanostructured Rafarma microspheres are intended for the treatment of liver cancer, and can also be used for radioembolization of other solid tumors.

Rafarma develops and implements a variety of radionuclide therapy technologies for the treatment of liver cancer and other solid tumors, which can provide a higher quality of life for the patient and delay the development of the disease.

The main idea of ??radionuclide therapy is the delivery of radioactive isotopes directly to the tumor and its subsequent destruction by ionizing radiation. Similar treatment technologies with different methods of delivering radionuclides have been successfully used to treat various diseases.

The principle of action of microspheres: embolization (blockage) of tumor vessels; selective accumulation in the tumor and its destruction by targeted irradiation; microspheres with Yttrium-90 are administered intra-arterially, which ensures that the maximum number of tumor foci is affected, so it is advisable to use them for the treatment of metastases.

Advantages of using microspheres: minimally invasive administration process; minimal damage to healthy tissue; damage to all foci and metastases of the tumor at once; the ability to deliver almost any dose of radiation to the tumor.

Efficiency of use: the average survival of patients when using microspheres with yttrium and chemotherapy increased from 13 to 27 months compared with the use of chemotherapy alone; 89% of patients have a positive response to treatment; 27% experience a decrease in tumor size.

ABOUT RAFARMA PHARMACEUTICALS

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields at the moment.

For more information, please visit https://www.noyarp.com

CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
+1 (307) 218-0292
Sheridan, Wyoming, 82801, USA

Source: Rafarma Pharmaceuticals, Inc.
https://www.globenewswire.com/news-release/2024/07/04/2908712/0/en/Rafarma-pharmaceutical-updates-registration-of-Rafarma-microspheres-in-South-Korea.html

They been saying that for 5 years. Per the last conference call in April, they still haven’t been able to find a auditor.

They reported that it would be completed by the end of Q1 or soon thereafter if possible.

No. Nothing. They can’t find anyone to audit the company.

Did I miss an announcement / PR here in the last two months?

https://www.noyarp.com/post/shareholders-meeting-official-responses-of-ceo-iliya-shpurov

https://www.noyarp.com/news/categories/appeals-of-the-owner

Thank you!

liza.babenko@gmail.com

Do you have Liza Babenko's email or the ability to add me to the WhatsApp group. I missed the call yesterday and was not given notice. She has told me multiple time she would add me but has yet to do so.

soon .0001

market cap rafa 8 million dollars someone should buy the shell use it for tax loss carry forward

Showmeprofits
Jan 31, 2024 3:53 PM

$RAFA Liza Babenko is inviting you to a scheduled Zoom meeting.

Topic: Liza Babenko's Zoom Meeting RAFARMA press conference
Time: Feb 2, 2024 12:00 PM Eastern Time (US and Canada)

Join Zoom Meeting
us06web.zoom.us/j/861623471...

Meeting ID: 861 6234 7186
Passcode: 852272
Join our Cloud HD Video Meeting
https://us06web.zoom.us

One of the questions answered by the CEO during the Zoom meeting...
9. How does Ilya see the company reaching $2 billion in assets as stated in his press release? The process of growing over the next two years?


Our efforts will be aimed at introducing advanced technologies on the one hand and transferring production to countries with low labour costs on the other hand. At the same time, we strive to maintain our competence in the production of pharmaceuticals. However, I must say that $2 billion is an assumption. We cannot guarantee shareholders that the value will be exactly that. We describe this not as a projection, but as our goal. We are currently aiming for a capitalization of $2 billion and are doing everything possible to achieve this.

32% hair cut today

no one likes what lisa is selling

Today
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173404089

$20 a share easily by 2025 if this becomes a $2 billion company

Post# 5981
5th paragraph

Where was this posted please?

RAFA head says $2 billion cap by the end of 2025...That's $83 million per month over the next 24 months!!!

Where did you see this? Thanks

$RAFA Liza Babenko is inviting you to a scheduled Zoom meeting.

Topic: Liza Babenko's Zoom Meeting_ RAFARMA PHARMACEUTICAL PRESS CONFERENCE
Time: Dec 18, 2023 12:00 PM Eastern Time (US and Canada)

Join Zoom Meeting
us06web.zoom.us/j/862948297...

Meeting ID: 862 9482 9794
Passcode: 564976

RAFA Website
https://www.noyarp.com/

Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.

Due to the changed geopolitical situation, the company was unable to complete the review of some of the assets that were set for audit consolidation, namely Kraspharma and Bebig. The Company will continue to provide its shareholders with regular unaudited financial statements of Kraspharma and Bebig. Once the geopolitical climate changes, the company intends to complete the audit of these two assets and add them to the consolidated audited accounts.
Meanwhile, the company is working on and acquiring several assets and projects located in Kazakhstan, Israel, El Salvador, Sri Lanka and Hong Kong.
The company is currently working with its auditor and will submit standard GAAP audit reports that will include the acquired assets. Announcements will also be made in the near future describing newly acquired assets and projects in which the company is involved.
New acquisitions will not dilute the current assets of the company's shareholders.
The recapitalization of the company will be carried out through preferred shares. Our goal is to restructure the company to expand our products and manufacturing capabilities into global markets while maintaining the original scale of operations.
We are going to focus on medical research and development, both in terms of devices and drugs. In addition, we are interested in creating partnerships to continue to benefit from new product launches. We hope to use the resulting innovative products to create a global innovative company worth at least $2 billion by the end of 2025.
After assessing market changes and ongoing research projects in recent years, the company's development directions until 2028 were formed. Its portfolio includes nuclear medicine, biotechnology products, SMART packaging, and biotechnology research and development.
Below is the company's strategy for 2023-2028:
1. Transfer of projects and experience to open markets. Instead of unsafe transactions with Russian assets, we transferred our experience to more stable markets. Production lines are moving to Hong Kong, Kazakhstan, South Korea, El Salvador and Sri Lanka;
2. Stopping the project in Uzbekistan. The project in Uzbekistan has been stopped until the legislation is clarified. The project is temporarily frozen, since the government of Uzbekistan has not yet begun to implement the decree of the President of the Republic on the commercial circulation of blood plasma, issued under our agreement. In this regard, we officially do not have the right to implement our project in Uzbekistan, but we are actively looking for a similar country in Central Asia;
3. Introduction of microspheres as medical devices in China and Korea. We continue to seek acquisitions in the global market to further expand our portfolio;
4. Completion of verification. The company expects that, taking into account the forced changes in its structure, the audit will be completed by the end of first quarter of 2024;
5. Additional investments. The company's management invests its own funds in the implementation of new projects by increasing the company's attracted capital without increasing the number of voting shares;
6. We plan to further capitalize and increase the profitability of existing assets:

?Medical polymers;

?Pharmaceutical substances and antibodies;

?Photopolymers and holographic products;

?Consumables for muon spectrography;

?Emulsion and colloidal photographic materials;

?Ultra-pure materials based on aluminum A5H and A6H (99.9999%) for microelectronics;

?Packaging materials for pharmaceuticals.
Rafarma has the potential to become a major driver of the modern healthcare industry in areas where we can do it best. We provide nuclear, technology and pharmaceutical solutions to hundreds of thousands of patients around the world. Our products are trusted by healthcare professionals and institutions around the world. Through a diversified product portfolio and a wide range of research projects, we strive to disseminate our work and our core values.
We believe that our commitment to saving and preserving the quality of life of patients, as well as the experience of our team, is the right combination to overcome this technological milestone. We focus on the areas we know best: nuclear medicine, new pharmaceuticals, medical devices and cancer treatment technologies. Our credo: we must save lives that should not be lost thanks to modern technological advances; we must preserve a quality of life that can be freed from unnecessary restrictions and suffering; and we must push medical progress forward.
The press conference with with shareholders hold on November 23, 2023 online on Zoom.

$RAFA - Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Center
$RAFA - Rapharma and Kelun Lifesciences have entered into a preliminary agreementhttps://t.co/9Vo7DELkBx pic.twitter.com/QFpR2mLhxR— Rafarma Pharmaceuticals Inc (@RafarmaPharma) December 6, 2023

$RAFA - Rafarma Pharmaceuticals Signed a Preliminary Agreement for Radiopharmaceutical Production Centerhttps://t.co/AnfNPhwAtM pic.twitter.com/1lIgbQSd8L— Rafarma Pharmaceuticals Inc (@RafarmaPharma) December 6, 2023

https://www.otcmarkets.com/otcapi/company/financial-report/385919/content

Faith

At least we know one of two things. 1. This is just a pos and we lose our money. 2. They get the audit done and show that its a real viable company and hit their 2 billion target in 2025 and we make a shit tone. At least theres no in between.

so we have a pulse coming back from the dead yea, still have a boat full of this pos

maybe one of the biggest off the radar stocks in all otc's.

Rafarma in Tashkent Pharma Park in Uzbekistan STOPPED! I've been waiting on it's completion for nearly as long as the completed audit!

https://finance.yahoo.com/news/rafarma-pharmaceutical-news-143000944.html

I don't know who Birdman is but thanks to Steven G Kashian pushing this garbage I'm sitting with a 92% loss, 7000 shares..

Then sell and move on.

I think rafa is in I C U doc gives it 1/2 of 1% chance of making it.

if rafa have x millions in the bank are we trading at cash value appox 8.3 million

You’re obsessed. Like a guy stalking his ex-girlfriend.

See you at a nickle!

Yes. Please leave. We’d love that.

think it's time to bail on this POS. Dead money. when it moves i''ll buy back, possibly.